Efficacy safety and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr81 trial
| dc.article.end-page | 14 | en |
| dc.article.start-page | 1 | en |
| dc.citation.doi | 10.1016/J.RPTH.2024.102615 | en |
| dc.contributor.author | A Leavitt | en |
| dc.contributor.author | Johnny Mahlangu | en |
| dc.contributor.author | P Raheja | en |
| dc.contributor.author | E Symington | en |
| dc.contributor.author | D Quon | en |
| dc.contributor.author | E et al | en |
| dc.date.accessioned | 2025-03-10T06:10:16Z | |
| dc.faculty | FACULTY OF HEALTH SCIENCES | en |
| dc.identifier.citation | WOS | en |
| dc.identifier.uri | https://hdl.handle.net/10539/44179 | |
| dc.journal.title | Efficacy safety and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr81 trial | en |
| dc.journal.volume | 8 | en |
| dc.title | Efficacy safety and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr81 trial | en |
| dc.type | Journal Article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Journal Article.pdf
- Size:
- 1.57 MB
- Format:
- Adobe Portable Document Format
- Description:
- Bitstream uploaded by REST Client